Julia Shifman, PhD

Mutations in RAS proteins are found in 30% of all human cancers, and efforts to design drugs that target these proteins have been largely unsuccessful. Recently, the FDA approved a drug that targets RAS carrying one particular mutation, emphasizing the urgent need to find new therapeutics that target additional RAS mutants. To that end, Dr. Shifman’s team is working to engineer Nore1A, a human protein known to inhibit pro-cancer activity, supplying it with the ability to penetrate inside cancer cells, where mutated RAS is located.

View Grant Recipient Profile